RxDoctor Payments DataLook up a doctor →

Amee Rozanc, PA

Physician Assistant · O Fallon, MONPI 1255516134

Payments from drug & device makers

$101,414in general payments, 2019–2025

Across 922 payments — averaging $109.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$52K
  • E.r. Squibb & Sons, L.L.C.$40K
  • Amgen$2K
  • Dermavant Sciences, Inc.$1K
  • AbbVie$1K
  • LEO Pharma Inc.$839
  • plus $5K from 22 others

What the payments were for

  • Consulting fees$4,5945%
  • Speaking & faculty fees$64,82964%
  • Travel & lodging$15,08115%
  • Food & beverage$16,48716%
  • Education$4230%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$101,414 in reported general payments places this provider in the 95th percentile of 1,380 physician assistant providers in Missouri.

See all physician assistant providers in Missouri

Medicare billing

Part B allowed, 2024
$80,634
Medicare patients
325
Services billed
2,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast20$113,597
Clobetasol Propionate73$2,669
Ketoconazole129$2,662
Calcipotriene13$1,303
Fluorouracil13$1,181
Triamcinolone Acetonide102$980
Metronidazole18$893
Clindamycin Phosphate14$795
Doxycycline Hyclate48$697
ValacyclovirValacyclovir Hcl14$361
Cephalexin13$322
Desonide11$148
Minoxidil12$145
Mupirocin17$120
Hydroxychloroquine Sulfate11$10

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,508$113,59720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,380 physician assistant providers in Missouri.

Other physician assistant in O Fallon

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →